Novartis Meningitis Blockbuster Strategy Key To Firm’s Vaccine Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis plans to submit ACWY meningitis BLA in the second half, putting Menveo on track for approval in 2009.
You may also be interested in...
Pressure For Bexsero: Fate Of Novartis Vaccines Unit Hangs On Success
The EU CHMP’s recommendation in favor of Novartis’ Meningitis B vaccine Bexsero is a positive turn for the company’s vaccines business, but with the division’s sales and profits languishing, some investors are wondering if Novartis should cut its losses and get out of the space.
Novartis Needs A Bigger Safety Database For Menveo, FDA Says
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.
Novartis Needs A Bigger Safety Database For Menveo, FDA Says
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.